GlassScriptPhysician profile
Julio Narvaez
NPI 1962427088
$1,761.65
in general payments reported to CMS, 2019-2025
23 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $110 · 2021: $205 · 2022: $451 · 2023: $175 · 2024: $540 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $871.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $870.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $225.36 | 2021-2024 | Omni Surgical System |
| Genentech USA, INC. | $193.48 | 2022-2025 | Vabysmo |
| Rxsight INC | $178.81 | 2021-2024 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
| Alcon Vision LLC | $158.66 | 2019-2025 | Rocklatan |
| Novartis Pharmaceuticals Corporation | $154.68 | 2021-2023 | |
| Oyster Point Pharma, INC. | $101.00 | 2023-2024 | Tyrvaya, Ryzumvi, Tyrvaya |
| Johnson & Johnson Surgical Vision, INC. | $91.08 | 2020-2022 | |
| Dompe US, INC. | $87.28 | 2019-2025 | Oxervate |
| Biotissue Holdings INC. | $80.89 | 2021-2024 | |
| Glaukos Corporation | $75.26 | 2019-2024 | Ce-Marked Kxla System, Photrexa |
| Apellis Pharmaceuticals, INC. | $66.48 | 2024 | Syfovre |
| Amgen INC. | $59.72 | 2024-2025 | Tepezza |
| Bausch & Lomb Americas INC. | $52.45 | 2024-2025 | Ic-8 Apthera Iol, Infuse, Xiidra |
| Harrow Eye, LLC | $48.82 | 2024 | Vevye |
| Carl Zeiss Meditec Ag | $38.80 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $25.48 | 2022 | |
| Thea Pharma INC. | $24.77 | 2023 | |
| Aerie Pharmaceuticals, INC. | $20.99 | 2019 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Iridex Corporation | $17.22 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $16.62 | 2024 | Xdemvy |
| Boston Scientific Corporation | $13.66 | 2025 | Wavewriter Alpha Prime 16 |
| Horizon Therapeutics Plc | $12.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julio Narvaez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.